Clinical Trial Update: Optimal Dose of Anti-lymphocyte Globulin in Kidney Transplant Recipients With Low Immunological Risk [Phase 1]

View source ↗

Summary

Phase 1 clinical trial assessing the optimal dose of anti-lymphocyte globulin in kidney transplant recipients at low immunological risk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Anti-lymphocyte Globulin (anti-lymphocyte globulin)

Snippet

Sponsor: Centre Hospitalier Universitaire de Besancon | Conditions: Renal Transplantation | Phase 1 | Status: NOT_YET_RECRUITING